BACKGROUND: Inflammation is associated with end-organ disease and mortality for people with human immunodeficiency virus (PWH). Ruxolitinib, a Jak 1/2 inhibitor, reduces systemic inflammation for individuals without human immunodeficiency virus (HIV) and HIV reservoir markers ex vivo. The goal of this trial was to determine safety and efficacy of ruxolitinib for PWH on antiretroviral therapy (ART). METHODS: AIDS Clinical Trials Group (ACTG) A5336 was an open-label, multisite, randomized controlled trial (RCT). Participants were randomly assigned (2:1) using centralized software to ruxolitinib (10 mg twice daily) plus stable ART for 5 weeks vs ART alone, stratified by efavirenz use. Eligible participants were suppressed on ART for ≥2 years, without comorbidities, and had >350 CD4+ T cells/µL. Primary endpoints were premature discontinuation, safety events, and change in plasma interleukin 6 (IL-6). Secondary endpoints included other measures of inflammation/immune activation and HIV reservoir. RESULTS: Sixty participants were enrolled from 16 May 2016 to 10 January 2018. Primary safety events occurred in 2.5% (1 participant) for ruxolitinib and 0% for controls (P = .67). Three participants (7.5%) prematurely discontinued ruxolitinib. By week 5, differences in IL-6 (mean fold change [FC], 0.93 vs 1.10; P = .18) and soluble CD14 (mean FC, 0.96 vs 1.08; relative FC, 0.96 [90% confidence interval {CI}, .90-1.02]) levels for ruxolitinib vs controls was observed. Ruxolitinib reduced CD4+ T cells expressing HLA-DR/CD38 (mean difference, -0.34% [90% CI, -.66% to -.12%]) and Bcl-2 (mean difference, -3.30% [90% CI, -4.72% to -1.87%]). CONCLUSIONS: In this RCT of healthy, virologically suppressed PWH on ART, ruxolitinib was well-tolerated. Baseline IL-6 levels were normal and showed no significant reduction. Ruxolitinib significantly decreased markers of immune activation and cell survival. Future studies of Jak inhibitors should target PWH with residual inflammation despite suppressive ART. CLINICAL TRIALS REGISTRATION: NCT02475655. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
BACKGROUND: Inflammation is associated with end-organ disease and mortality for people with human immunodeficiency virus (PWH). Ruxolitinib, a Jak 1/2 inhibitor, reduces systemic inflammation for individuals without human immunodeficiency virus (HIV) and HIV reservoir markers ex vivo. The goal of this trial was to determine safety and efficacy of ruxolitinib for PWH on antiretroviral therapy (ART). METHODS: AIDS Clinical Trials Group (ACTG) A5336 was an open-label, multisite, randomized controlled trial (RCT). Participants were randomly assigned (2:1) using centralized software to ruxolitinib (10 mg twice daily) plus stable ART for 5 weeks vs ART alone, stratified by efavirenz use. Eligible participants were suppressed on ART for ≥2 years, without comorbidities, and had >350 CD4+ T cells/µL. Primary endpoints were premature discontinuation, safety events, and change in plasma interleukin 6 (IL-6). Secondary endpoints included other measures of inflammation/immune activation and HIV reservoir. RESULTS: Sixty participants were enrolled from 16 May 2016 to 10 January 2018. Primary safety events occurred in 2.5% (1 participant) for ruxolitinib and 0% for controls (P = .67). Three participants (7.5%) prematurely discontinued ruxolitinib. By week 5, differences in IL-6 (mean fold change [FC], 0.93 vs 1.10; P = .18) and soluble CD14 (mean FC, 0.96 vs 1.08; relative FC, 0.96 [90% confidence interval {CI}, .90-1.02]) levels for ruxolitinib vs controls was observed. Ruxolitinib reduced CD4+ T cells expressing HLA-DR/CD38 (mean difference, -0.34% [90% CI, -.66% to -.12%]) and Bcl-2 (mean difference, -3.30% [90% CI, -4.72% to -1.87%]). CONCLUSIONS: In this RCT of healthy, virologically suppressed PWH on ART, ruxolitinib was well-tolerated. Baseline IL-6 levels were normal and showed no significant reduction. Ruxolitinib significantly decreased markers of immune activation and cell survival. Future studies of Jak inhibitors should target PWH with residual inflammation despite suppressive ART. CLINICAL TRIALS REGISTRATION: NCT02475655. Published by Oxford University Press for the Infectious Diseases Society of America 2021.
Entities:
Keywords:
HIV; Jak inhibitors; immune activation; inflammation; reservoir
Authors: Haifa Kathrin Al-Ali; Martin Griesshammer; Philipp le Coutre; Cornelius F Waller; Anna Marina Liberati; Philippe Schafhausen; Renato Tavares; Pilar Giraldo; Lynda Foltz; Pia Raanani; Vikas Gupta; Bayane Tannir; Julian Perez Ronco; Jagannath Ghosh; Bruno Martino; Alessandro M Vannucchi Journal: Haematologica Date: 2016-05-31 Impact factor: 9.941
Authors: Anthony R Cillo; David Vagratian; Margaret A Bedison; Elizabeth M Anderson; Mary F Kearney; Elizabeth Fyne; Dianna Koontz; John M Coffin; Michael Piatak; John W Mellors Journal: J Clin Microbiol Date: 2014-09-03 Impact factor: 5.948
Authors: Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly Journal: Nat Med Date: 2009-06-21 Impact factor: 53.440
Authors: Nathan W Cummins; Amy M Sainski; Haiming Dai; Sekar Natesampillai; Yuan-Ping Pang; Gary D Bren; Maria Cristina Miranda de Araujo Correia; Rahul Sampath; Stacey A Rizza; Daniel O'Brien; Joseph D Yao; Scott H Kaufmann; Andrew D Badley Journal: J Virol Date: 2016-03-28 Impact factor: 5.103
Authors: Leslie R Cockerham; Janet D Siliciano; Elizabeth Sinclair; Una O'Doherty; Sarah Palmer; Steven A Yukl; Matt C Strain; Nicolas Chomont; Frederick M Hecht; Robert F Siliciano; Douglas D Richman; Steven G Deeks Journal: PLoS One Date: 2014-10-23 Impact factor: 3.240
Authors: Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Vikas Gupta; John F DiPersio; John V Catalano; Michael W N Deininger; Carole B Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth O Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Mark Jones; Deanna Kornacki; Kang Sun; Hagop Kantarjian Journal: J Hematol Oncol Date: 2017-02-22 Impact factor: 17.388
Authors: Andre C Kalil; Thomas F Patterson; Aneesh K Mehta; Kay M Tomashek; Cameron R Wolfe; Varduhi Ghazaryan; Vincent C Marconi; Guillermo M Ruiz-Palacios; Lanny Hsieh; Susan Kline; Victor Tapson; Nicole M Iovine; Mamta K Jain; Daniel A Sweeney; Hana M El Sahly; Angela R Branche; Justino Regalado Pineda; David C Lye; Uriel Sandkovsky; Anne F Luetkemeyer; Stuart H Cohen; Robert W Finberg; Patrick E H Jackson; Babafemi Taiwo; Catharine I Paules; Henry Arguinchona; Nathaniel Erdmann; Neera Ahuja; Maria Frank; Myoung-Don Oh; Eu-Suk Kim; Seow Y Tan; Richard A Mularski; Henrik Nielsen; Philip O Ponce; Barbara S Taylor; LuAnn Larson; Nadine G Rouphael; Youssef Saklawi; Valeria D Cantos; Emily R Ko; John J Engemann; Alpesh N Amin; Miki Watanabe; Joanne Billings; Marie-Carmelle Elie; Richard T Davey; Timothy H Burgess; Jennifer Ferreira; Michelle Green; Mat Makowski; Anabela Cardoso; Stephanie de Bono; Tyler Bonnett; Michael Proschan; Gregory A Deye; Walla Dempsey; Seema U Nayak; Lori E Dodd; John H Beigel Journal: N Engl J Med Date: 2020-12-11 Impact factor: 176.079
Authors: E A Innis; C Levinger; M A Szaniawski; E S C P Williams; J Alcamí; A Bosque; J T Schiffer; M Coiras; A M Spivak; V Planelles Journal: Biochem Pharmacol Date: 2021-10-26 Impact factor: 5.858
Authors: Lesley R de Armas; Christina Gavegnano; Suresh Pallikkuth; Stefano Rinaldi; Li Pan; Emilie Battivelli; Eric Verdin; Ramzi T Younis; Rajendra Pahwa; Siôn L Williams; Raymond F Schinazi; Savita Pahwa Journal: Front Immunol Date: 2021-08-31 Impact factor: 7.561
Authors: Jennifer Beecker; Curtis Cooper; Mark G Kirchhof; Anton L Pozniak; Juergen K Rockstroh; Kim A Papp; Jan P Dutz; Melinda J Gooderham; Robert Gniadecki; Chih-Ho Hong; Charles W Lynde; Catherine Maari; Yves Poulin; Ronald B Vender; Sharon L Walmsley Journal: Dermatol Ther (Heidelb) Date: 2022-04-21
Authors: Selwyn J Hurwitz; Sijia Tao; Christina Gavegnano; Yong Jiang; Randall L Tressler; Athe Tsibris; Carlos Del Rio; Edgar T Overton; Michael M Lederman; Amy Kantor; Carlee Moser; James J Kohler; Jeffrey Lennox; Vincent C Marconi; Charles W Flexner; Raymond F Schinazi Journal: J Clin Pharmacol Date: 2021-07-23 Impact factor: 2.860
Authors: John Kanazawa; Sara Gianella; Susanna Concha-Garcia; Jeff Taylor; Andy Kaytes; Christopher Christensen; Hursch Patel; Samuel Ndukwe; Stephen Rawlings; Steven Hendrickx; Susan Little; Brandon Brown; Davey Smith; Karine Dubé Journal: PLoS One Date: 2021-07-16 Impact factor: 3.240